Evidence map›Paper›PMID 36653039›Full record

ArticleBMJ case reports2023

Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline

Benjamin T Berger, Matthew K Labriola, Emmanuel S Antonarakis, Andrew J Armstrong

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Genotoxicity of cancer therapies and the risk of secondary malignancies: toward personalized prevention.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Benjamin T BergerDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA benjamin.t.berger@duke.edu andrew.armstrong@duke.edu.ORCID http://orcid.org/0000-0003-2149-6677
Matthew K LabriolaDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Emmanuel S AntonarakisDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Academic Health Center, Minneapolis, Minnesota, USA.
Andrew J ArmstrongDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA benjamin.t.berger@duke.edu andrew.armstrong@duke.edu.
Duke University · USDuke Medical Center · USUniversity of Minnesota Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the case of a patient with germline

Indexed as

Prostatic Neoplasms, Castration-ResistantAndrogen AntagonistsAndrogensCheckpoint Kinase 2Germ CellsGerm-Line MutationHumansMaleProgrammed Cell Death 1 ReceptorProstate-Specific AntigenAndrogen AntagonistsAndrogensCheckpoint Kinase 2CHEK2 protein, humanProgrammed Cell Death 1 ReceptorProstate-Specific AntigenCancer interventionOncologyProstateProstate Cancer

Identifiers

PMID36653039
PMCPMC9853129
OpenAlexW4317233768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.